Do analysts recommend PRPO or SYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PRPO or SYRA?

Precipio has higher revenue and earnings than Syra Health. Precipio is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $27.20M 1.48 -$360K -$0.64 N/A Syra Health $7.98M 1.46 -$2.94M $0.01 84.20

Is PRPO or SYRA more profitable?

Precipio has a net margin of -4.47% compared to Syra Health's net margin of -54.90%. Precipio's return on equity of -8.49% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% Syra Health -54.90% -131.94% -99.19%

Does the media refer more to PRPO or SYRA?

In the previous week, Precipio had 2 more articles in the media than Syra Health. MarketBeat recorded 3 mentions for Precipio and 1 mentions for Syra Health. Precipio's average media sentiment score of 1.11 beat Syra Health's score of 0.00 indicating that Precipio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syra Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PIII or SYRA?

P3 Health Partners presently has a consensus price target of $17.00, suggesting a potential upside of 310.63%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to PIII or SYRA?

In the previous week, P3 Health Partners had 2 more articles in the media than Syra Health. MarketBeat recorded 3 mentions for P3 Health Partners and 1 mentions for Syra Health. P3 Health Partners' average media sentiment score of 0.93 beat Syra Health's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment P3 Health Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syra Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SYRA or BTMD?

biote has a consensus target price of $2.50, indicating a potential upside of 125.23%. Given biote's stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, SYRA or BTMD?

biote has higher revenue and earnings than Syra Health. biote is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syra Health $7.98M 1.46 -$2.94M $0.01 84.20 biote $183.53M 0.22 $27.05M $0.11 10.09

Is SYRA or BTMD more profitable?

biote has a net margin of 3.19% compared to Syra Health's net margin of -54.90%. biote's return on equity of -22.33% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets Syra Health -54.90% -131.94% -99.19% biote 3.19% -22.33% 12.10%

Does the media prefer SYRA or BTMD?

In the previous week, biote had 3 more articles in the media than Syra Health. MarketBeat recorded 4 mentions for biote and 1 mentions for Syra Health. biote's average media sentiment score of 0.45 beat Syra Health's score of 0.00 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syra Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACH or SYRA?

Accendra Health currently has a consensus price target of $1.50, indicating a potential upside of 462.64%. Given Accendra Health's stronger consensus rating and higher possible upside, research analysts clearly believe Accendra Health is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accendra Health 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor ACH or SYRA?

In the previous week, Accendra Health had 1 more articles in the media than Syra Health. MarketBeat recorded 2 mentions for Accendra Health and 1 mentions for Syra Health. Syra Health's average media sentiment score of 0.00 beat Accendra Health's score of -0.25 indicating that Syra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syra Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DCGO or SYRA?

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 742.20%. Given DocGo's stronger consensus rating and higher possible upside, equities research analysts plainly believe DocGo is more favorable than Syra Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, DCGO or SYRA?

Syra Health has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $294.72M 0.09 -$182.40M -$1.96 N/A Syra Health $7.98M 1.46 -$2.94M $0.01 84.20

Is DCGO or SYRA more profitable?

Syra Health has a net margin of -54.90% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Syra Health -54.90% -131.94% -99.19%

Syra Health (SYRA) Competitors

$0.86 +0.02 (+2.11%)

As of 03:51 PM Eastern

Compare

SYRA vs. PRPO, PIII, BTMD, ACH, and DCGO

Should you buy Syra Health stock or one of its competitors? Syra Health's main competitors and comparable companies include Precipio (PRPO), P3 Health Partners (PIII), biote (BTMD), Accendra Health (ACH), and DocGo (DCGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Syra Health compare to Precipio?

Precipio (NASDAQ:PRPO) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, Precipio had 2 more articles in the media than Syra Health. MarketBeat recorded 3 mentions for Precipio and 1 mentions for Syra Health. Precipio's average media sentiment score of 1.11 beat Syra Health's score of 0.00 indicating that Precipio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syra Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.4% of Precipio shares are owned by institutional investors. Comparatively, 4.8% of Syra Health shares are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 36.5% of Syra Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Precipio has a net margin of -4.47% compared to Syra Health's net margin of -54.90%. Precipio's return on equity of -8.49% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Syra Health	-54.90%	-131.94%	-99.19%

Precipio has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Syra Health has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market.

Precipio has higher revenue and earnings than Syra Health. Precipio is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$27.20M	1.48	-$360K	-$0.64	N/A
Syra Health	$7.98M	1.46	-$2.94M	$0.01	84.20

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Precipio beats Syra Health on 10 of the 14 factors compared between the two stocks.

How does Syra Health compare to P3 Health Partners?

P3 Health Partners (NASDAQ:PIII) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

P3 Health Partners has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Syra Health has a beta of 2.91, suggesting that its share price is 191% more volatile than the broader market.

Syra Health has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.50B	0.02	-$147.95M	-$33.00	N/A
Syra Health	$7.98M	1.46	-$2.94M	$0.01	84.20

In the previous week, P3 Health Partners had 2 more articles in the media than Syra Health. MarketBeat recorded 3 mentions for P3 Health Partners and 1 mentions for Syra Health. P3 Health Partners' average media sentiment score of 0.93 beat Syra Health's score of 0.00 indicating that P3 Health Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
P3 Health Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syra Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

P3 Health Partners presently has a consensus price target of $17.00, suggesting a potential upside of 310.63%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 4.8% of Syra Health shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 36.5% of Syra Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

P3 Health Partners has a net margin of -6.55% compared to Syra Health's net margin of -54.90%. P3 Health Partners' return on equity of 0.00% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Syra Health	-54.90%	-131.94%	-99.19%

Summary

P3 Health Partners beats Syra Health on 11 of the 16 factors compared between the two stocks.

How does Syra Health compare to biote?

Syra Health (NASDAQ:SYRA) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

4.8% of Syra Health shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 36.5% of Syra Health shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, biote had 3 more articles in the media than Syra Health. MarketBeat recorded 4 mentions for biote and 1 mentions for Syra Health. biote's average media sentiment score of 0.45 beat Syra Health's score of 0.00 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syra Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syra Health has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, biote has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

biote has a net margin of 3.19% compared to Syra Health's net margin of -54.90%. biote's return on equity of -22.33% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syra Health	-54.90%	-131.94%	-99.19%
biote	3.19%	-22.33%	12.10%

biote has higher revenue and earnings than Syra Health. biote is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syra Health	$7.98M	1.46	-$2.94M	$0.01	84.20
biote	$183.53M	0.22	$27.05M	$0.11	10.09

biote has a consensus target price of $2.50, indicating a potential upside of 125.23%. Given biote's stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

biote beats Syra Health on 14 of the 17 factors compared between the two stocks.

How does Syra Health compare to Accendra Health?

Accendra Health (NYSE:ACH) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Accendra Health has a net margin of -11.41% compared to Syra Health's net margin of -54.90%. Accendra Health's return on equity of -4.02% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
Syra Health	-54.90%	-131.94%	-99.19%

4.8% of Syra Health shares are owned by institutional investors. 2.3% of Accendra Health shares are owned by insiders. Comparatively, 36.5% of Syra Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Accendra Health currently has a consensus price target of $1.50, indicating a potential upside of 462.64%. Given Accendra Health's stronger consensus rating and higher possible upside, research analysts clearly believe Accendra Health is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Syra Health has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.01	-$1.10B	-$3.91	N/A
Syra Health	$7.98M	1.46	-$2.94M	$0.01	84.20

In the previous week, Accendra Health had 1 more articles in the media than Syra Health. MarketBeat recorded 2 mentions for Accendra Health and 1 mentions for Syra Health. Syra Health's average media sentiment score of 0.00 beat Accendra Health's score of -0.25 indicating that Syra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syra Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Accendra Health has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Syra Health has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market.

Summary

Accendra Health beats Syra Health on 8 of the 15 factors compared between the two stocks.

How does Syra Health compare to DocGo?

DocGo (NASDAQ:DCGO) and Syra Health (NASDAQ:SYRA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Syra Health has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Syra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$294.72M	0.09	-$182.40M	-$1.96	N/A
Syra Health	$7.98M	1.46	-$2.94M	$0.01	84.20

In the previous week, DocGo and DocGo both had 1 articles in the media. DocGo's average media sentiment score of 1.79 beat Syra Health's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Very Positive
Syra Health	Neutral

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 742.20%. Given DocGo's stronger consensus rating and higher possible upside, equities research analysts plainly believe DocGo is more favorable than Syra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Syra Health has a net margin of -54.90% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Syra Health	-54.90%	-131.94%	-99.19%

DocGo has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Syra Health has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market.

56.4% of DocGo shares are held by institutional investors. Comparatively, 4.8% of Syra Health shares are held by institutional investors. 5.1% of DocGo shares are held by company insiders. Comparatively, 36.5% of Syra Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

DocGo beats Syra Health on 9 of the 15 factors compared between the two stocks.

Get Syra Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRA vs. The Competition

Export

Metric	Syra Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.91M	$10.51B	$7.44B	$12.94B
Dividend Yield	N/A	2.58%	2.50%	27.63%
P/E Ratio	-1.32	28.45	192.52	18.55
Price / Sales	1.49	4.78	567.95	76.22
Price / Cash	N/A	116.03	76.54	51.88
Price / Book	1.39	5.07	10.29	5.85
Net Income	-$2.94M	$315.68M	$3.50B	$380.67M
7 Day Performance	-0.02%	-1.26%	-5.37%	-4.97%
1 Month Performance	-3.39%	-5.60%	-8.55%	-6.95%
1 Year Performance	N/A	9.92%	0.43%	-5.99%

Syra Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRA Syra Health	N/A	$0.86 +2.1%	N/A	+1,175.8%	$11.91M	$7.98M	N/A	78	Gap Down
PRPO Precipio	1.0181 of 5 stars	$23.19 -1.4%	N/A	+28.2%	$42.10M	$24.05M	N/A	71	News Coverage Positive News Analyst Forecast
PIII P3 Health Partners	2.9751 of 5 stars	$5.31 -5.7%	$17.00 +220.2%	-53.7%	$40.88M	$1.46B	N/A	320	News Coverage Positive News Short Interest Decrease
BTMD biote	4.6557 of 5 stars	$1.17 +5.4%	$2.50 +113.7%	-61.6%	$39.88M	$192.22M	10.64	223
ACH Accendra Health	2.8845 of 5 stars	$0.45 -5.3%	$1.50 +235.1%	N/A	$36.37M	$2.73B	N/A	6,500	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRA) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syra Health (SYRA) Competitors

SYRA vs. PRPO, PIII, BTMD, ACH, and DCGO

How does Syra Health compare to Precipio?

Summary

How does Syra Health compare to P3 Health Partners?

Summary

How does Syra Health compare to biote?

Summary

How does Syra Health compare to Accendra Health?

Summary

How does Syra Health compare to DocGo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRA vs. The Competition

Syra Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syra Health (SYRA) Competitors

SYRA vs. PRPO, PIII, BTMD, ACH, and DCGO

How does Syra Health compare to Precipio?

Does the media refer more to PRPO or SYRA?

Do insiders and institutionals hold more shares of PRPO or SYRA?

Is PRPO or SYRA more profitable?

Which has more risk and volatility, PRPO or SYRA?

Which has higher earnings and valuation, PRPO or SYRA?

Do analysts recommend PRPO or SYRA?

Summary

How does Syra Health compare to P3 Health Partners?

Which has more risk & volatility, PIII or SYRA?

Which has stronger valuation and earnings, PIII or SYRA?

Does the media refer more to PIII or SYRA?

Do analysts rate PIII or SYRA?

Do institutionals & insiders have more ownership in PIII or SYRA?

Is PIII or SYRA more profitable?

Summary

How does Syra Health compare to biote?

Do institutionals and insiders have more ownership in SYRA or BTMD?

Does the media prefer SYRA or BTMD?

Which has more risk and volatility, SYRA or BTMD?

Is SYRA or BTMD more profitable?

Which has preferable earnings & valuation, SYRA or BTMD?

Do analysts rate SYRA or BTMD?

Summary

How does Syra Health compare to Accendra Health?

Is ACH or SYRA more profitable?

Do institutionals & insiders have more ownership in ACH or SYRA?

Do analysts rate ACH or SYRA?

Which has better valuation & earnings, ACH or SYRA?

Does the media favor ACH or SYRA?

Which has more volatility and risk, ACH or SYRA?

Summary

How does Syra Health compare to DocGo?

Which has stronger valuation & earnings, DCGO or SYRA?

Does the media refer more to DCGO or SYRA?

Do analysts prefer DCGO or SYRA?

Is DCGO or SYRA more profitable?

Which has more risk & volatility, DCGO or SYRA?

Do insiders and institutionals have more ownership in DCGO or SYRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRA vs. The Competition

Syra Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools